Tag Archives: Dr. Laurenz Kellenberger

Basilea Pharmaceutica Acquires Novel Antibiotics Program Targeting Multidrug-Resistant Gram-Negative Bacteria

(IN BRIEF) Basilea Pharmaceutica Ltd (SIX: BSLN), a biopharmaceutical company specializing in severe bacterial and fungal infection treatments, has announced an asset purchase agreement with Spexis AG (SIX: SPEX) for a preclinical antibiotics program aimed at combating Gram-negative bacteria, including … Read the full press release